Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline Review, H1 2017, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape.
Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 25, 27, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 5, 1 and 1 molecules, respectively.
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
4SC AG
AbbVie Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics Sarl
Affimed GmbH
Alfa Wassermann SpA
Alissa Pharma
Amgen Inc
Arno Therapeutics Inc
Bristol-Myers Squibb Company
Celgene Corp
Cell Medica Ltd
Cellectis SA
Celleron Therapeutics Ltd
Cellular Biomedicine Group Inc
Constellation Pharmaceuticals Inc
Cornerstone Pharmaceuticals Inc
Curis Inc
Faron Pharmaceuticals Oy
Incyte Corp
Kite Pharma Inc
MedImmune LLC
Merck & Co Inc
Merck KGaA
Mesoblast Ltd
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc
Molecular Templates Inc
NantKwest Inc
NBE-Therapeutics AG
Pfizer Inc
Philogen SpA
Regeneron Pharmaceuticals Inc
Rhizen Pharmaceuticals SA
Rich Pharmaceuticals Inc
Seattle Genetics Inc
Selvita SA
Spectrum Pharmaceuticals Inc
Stemline Therapeutics Inc
Syndax Pharmaceuticals Inc
Taiwan Liposome Company Ltd
Theravectys SA
TRACON Pharmaceuticals Inc
Trillium Therapeutics Inc
'
Table of Contents
Table of Contents 2
Introduction 5
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Overview 6
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Therapeutics Development 7
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Therapeutics Assessment 18
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Companies Involved in Therapeutics Development 30
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drug Profiles 53
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects 389
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Discontinued Products 392
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Product Development Milestones 393
Appendix 408
List of Tables
Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by 4SC AG, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by AbbVie Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Actinium Pharmaceuticals Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by ADC Therapeutics Sarl, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Affimed GmbH, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Alfa Wassermann SpA, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Alissa Pharma, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Amgen Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Arno Therapeutics Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Bristol-Myers Squibb Company, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celgene Corp, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cell Medica Ltd, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellectis SA, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Celleron Therapeutics Ltd, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cellular Biomedicine Group Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Constellation Pharmaceuticals Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Cornerstone Pharmaceuticals Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Curis Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Faron Pharmaceuticals Oy, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Incyte Corp, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Kite Pharma Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by MedImmune LLC, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Merck & Co Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Merck KGaA, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Mesoblast Ltd, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Mirati Therapeutics Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Molecular Templates Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by NantKwest Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by NBE-Therapeutics AG, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Pfizer Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Philogen SpA, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rhizen Pharmaceuticals SA, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Rich Pharmaceuticals Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Seattle Genetics Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Selvita SA, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Stemline Therapeutics Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Syndax Pharmaceuticals Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Taiwan Liposome Company Ltd, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Theravectys SA, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by TRACON Pharmaceuticals Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Pipeline by Trillium Therapeutics Inc, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, H1 2017 (Contd..1), H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Dormant Projects, H1 2017 (Contd..2), H1 2017
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Discontinued Products, H1 2017
List of Figures
Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
